Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...

For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

A new drug, donanemab, is being hailed as a turning point in the fight against Alzheimer's, after a global trial confirms it slows cognitive decline. The antibody medicine helps in the early ...

USF’s Memory Disorders Clinic fielding requests from patients and their families hoping that Donanemab can slow progressive brain disorder. Recently approved medication is showing success at ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...

Lecanemab and donanemab slow down the early stages of the disease - which is the most common form of dementia. But Alzheimer's Research UK says the NHS is not ready to roll out the drugs ...